Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Total Current Liabilities (2016 - 2025)

Coherus Oncology's Total Current Liabilities history spans 13 years, with the latest figure at $140.4 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 50.39% year-over-year to $140.4 million; the TTM value through Dec 2025 reached $140.4 million, down 50.39%, while the annual FY2025 figure was $140.4 million, 50.39% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $140.4 million at Coherus Oncology, down from $372.3 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $538.3 million in Q1 2024 and bottomed at $123.4 million in Q1 2023.
  • The 5-year median for Total Current Liabilities is $256.3 million (2021), against an average of $255.5 million.
  • The largest annual shift saw Total Current Liabilities soared 336.2% in 2024 before it tumbled 52.62% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $165.3 million in 2021, then fell by 16.11% to $138.7 million in 2022, then surged by 139.21% to $331.8 million in 2023, then decreased by 14.71% to $283.0 million in 2024, then crashed by 50.39% to $140.4 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Total Current Liabilities are $140.4 million (Q4 2025), $372.3 million (Q3 2025), and $263.6 million (Q2 2025).